In this week’s episode, we break down three major biotech stories from May 9–16, 2025:

• The White House revives the “Most Favored Nation” drug pricing model, aiming to tie Medicare prices to those paid abroad, but with little enforcement or funding, it’s more signal than substance.
• Novo Nordisk strikes a $2.2B deal to develop oral obesity drugs with Septerna, then sees the surprise resignation of its longtime CEO amid competitive pressure from Eli Lilly.
• Biohaven’s stock tumbles 22% after the FDA delays its review of troriluzole, a rare disease therapy, citing the need for an advisory committee meeting.

Subscribe for weekly biotech recaps plus deep-dive interviews with industry and academic experts.

This Week in Biotech #51 (May 2–10, 2025)
CRISPR’s cholesterol breakthrough, the FDA’s new CBER chief rattles markets, NIH faces historic budget cuts, and Charles River pivots as animal testing falls out of favor. Plus: Gilead, Vertex, and key approvals you might’ve missed.

📺 This is a short weekly recap video, perfect for staying current in just a few minutes.

Subscribe to our FREE newsletter on biotechblueprint.substack.com

Biotech Blueprint is a newsletter and a podcast where biotech professionals and industry insiders come together to unpack the trends, challenges, and breakthroughs shaping the future of biotech. In our first episode, I sat down with Hartaj Singh, veteran biotech analyst and founder of Biotech Capital Compass, for a candid conversation about career pivots, the rise of mRNA cancer vaccines, AI in drug discovery, and what recent layoffs in the public and private sectors signal for the industry's next chapter. We also dive into how we each curate biotech news, why community matters, and what it means to build a life and career in this ever-evolving space. This is just the beginning of a series aimed at honest, thoughtful discussions with those moving biotech forward.